Report Company Directory

KineMaster

• CORRECTING and REPLACING, NexStreaming announces NexPlayer Becomes a Unity Verified Solutions Partner by BusinessWire
• ATTENTION - RECTIFICATION : Revoici la dépêche corrigée: NexStreaming annonce que NexPlayer devient un partenaire Solutions agréées Unity by BusinessWire
• NexStreaming lance des lecteurs SDK NexPlayer pour la PlayStation de Sony et les consoles de jeu Xbox Series X de Microsoft by BusinessWire
• NexStreaming Releases NexPlayer SDK for Sony PlayStation and Microsoft Xbox Series X Gaming Consoles by BusinessWire
• TenTime utilise le lecteur NexPlayer pour le lancement de la première plateforme de streaming VSDA sur Android, Samsung Tizen et LG WebOS destinée aux arabophones by BusinessWire
• TenTime Uses NexPlayer to Launch the First Arabic SVOD Streaming Platform on Android, Samsung Tizen and LG WebOS by BusinessWire
• NexStreaming releases NexPlayer for Nintendo Switch™ by BusinessWire
• KineMaster Corporation: 1 director by SmartInsider
• NexPlayer Releases New Audio Experience for OTT Solutions by BusinessWire
• NexPlayer and NUNC Power Vienna State Opera Tizen App by BusinessWire

Kinepolis Group NV

• Benelux Morning Notes by ING Financial Markets
• Benelux Morning Notes by ING Financial Markets
• Morning Notes : ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HYL BB, IBAB BB, KIN BB, MTLS US, VGP BB, AZE BB, ZEAL DC by KBC Securities
• Kinepolis Group Lower results, as expected, impacted by less visitors but higher dividend by KBC Securities
• Kinepolis boekt solide resultaten in 2025 by GlobeNewsWire
• Kinepolis a réalisé des résultats solides en 2025 by GlobeNewsWire
• Kinepolis delivered solid results in 2025 by GlobeNewsWire
• Benelux Morning Notes by ING Financial Markets
• Morning Notes : AED BB, OPTI BB, HOMI BB, KIN BB, MONT BB by KBC Securities
• Benelux Morning Notes by ING Financial Markets

KINETA INC

• Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024) by GlobeNewsWire
• Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors by GlobeNewsWire
• Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 by GlobeNewsWire
• Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1 by GlobeNewsWire
• Kineta, Inc Transitioning from Nasdaq to OTC Markets by GlobeNewsWire
• Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer by GlobeNewsWire
• Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences by GlobeNewsWire
• Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities by GlobeNewsWire
• Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial by GlobeNewsWire
• Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update by GlobeNewsWire

KINETANA INTERNATIONAL BIOTECH PHARMA LTD.

Kinetic Concepts Inc.